Suppr超能文献

应用估计量框架,通过基于参考的多重插补模拟试验,研究信息性删失。

Application of the estimand framework for an emulated trial using reference based multiple imputation to investigate informative censoring.

机构信息

Division of Infectious Diseases, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.

Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.

出版信息

BMC Med Res Methodol. 2024 Oct 18;24(1):245. doi: 10.1186/s12874-024-02364-6.

Abstract

BACKGROUND

The ICH E9 (R1) addendum on Estimands and Sensitivity analysis in Clinical trials proposes a framework for the design and analysis of clinical trials aimed at improving clarity around the definition of the targeted treatment effect (the estimand) of a study.

METHODS

We adopt the estimand framework in the context of a study using "trial emulation" to estimate the risk of pneumocystis pneumonia, an opportunistic disease contracted by people living with HIV and AIDS having a weakened immune system, when considering two antibiotic treatment regimes for stopping antibiotic prophylaxis treatment against this disease. A "while on treatment" strategy has been implemented for post-randomisation (intercurrent) events. We then perform a sensitivity analysis using reference based multiple imputation to model a scenario in which patients lost to follow-up stop taking prophylaxis.

RESULTS

The primary analysis indicated a protective effect for the new regime which used viral suppression as prophylaxis stopping criteria (hazard ratio (HR) 0.78, 95% confidence interval [0.69, 0.89], p < 0.001). For the sensitivity analysis, when we apply the "jump to off prophylaxis" approach, the hazard ratio is almost the same compared to that from the primary analysis (HR 0.80 [0.69, 0.95], p = 0.009). The sensitivity analysis confirmed that the new regime exhibits a clear improvement over the existing guidelines for PcP prophylaxis when those lost to follow-up "jump to off prophylaxis".

CONCLUSIONS

Our application using reference based multiple imputation demonstrates the method's flexibility and simplicity for sensitivity analyses in the context of the estimand framework for (emulated) trials.

摘要

背景

ICH E9(R1)附录中关于临床试验中的目标值和敏感性分析提出了一个框架,旨在提高对研究目标治疗效果(目标值)定义的清晰度,从而设计和分析临床试验。

方法

我们在使用“试验模拟”的研究背景下采用目标值框架,估计在考虑两种停止针对这种疾病的抗生素预防治疗的抗生素治疗方案时,艾滋病毒和艾滋病患者免疫功能减弱的人患机会性肺炎(卡氏肺孢子虫肺炎)的风险。针对随机化后(并发)事件实施了“治疗中”策略。然后,我们使用基于参考的多重插补进行敏感性分析,以模拟患者失访停止预防的情况。

结果

主要分析表明,新方案使用病毒抑制作为预防停药标准具有保护作用(风险比(HR)0.78,95%置信区间[0.69,0.89],p<0.001)。对于敏感性分析,当我们应用“跳转到停用预防”方法时,与主要分析相比,风险比几乎相同(HR 0.80 [0.69,0.95],p=0.009)。敏感性分析证实,当失访患者“跳转到停用预防”时,新方案与现有的 PcP 预防指南相比,对 PcP 预防具有明显改善。

结论

我们使用基于参考的多重插补的应用证明了该方法在(模拟)试验的目标值框架下进行敏感性分析的灵活性和简单性。

相似文献

6
Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.标志着临床试验新思维的 2 年:效应量估计之旅。
Ther Innov Regul Sci. 2022 Jul;56(4):637-650. doi: 10.1007/s43441-022-00402-3. Epub 2022 Apr 24.
7
Incorporating estimands into clinical trial statistical analysis plans.将估计量纳入临床试验统计分析计划中。
Clin Trials. 2022 Jun;19(3):285-291. doi: 10.1177/17407745221080463. Epub 2022 Mar 8.
8
Estimands in hematologic oncology trials.血液肿瘤学试验中的估计目标。
Pharm Stat. 2021 Jul;20(4):793-805. doi: 10.1002/pst.2108. Epub 2021 Mar 8.
10
Stopping PCP prophylaxis after suppressing HIV.
GMHC Treat Issues. 1999 Apr;13(4):4-5.

本文引用的文献

7
Reference-based sensitivity analysis for time-to-event data.基于参考的生存时间数据敏感性分析。
Pharm Stat. 2019 Nov;18(6):645-658. doi: 10.1002/pst.1954. Epub 2019 Jul 15.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验